Sector: Healthcare | Industry: Advanced Medical Equipment & Technology |
Company Contact | |
Address: | 100 Cummings Ctr Ste 465e BEVERLY MA 01915-6143 |
Tel: | N/A |
Website: | https://www.hamiltonthorne.com |
IR: | See website |
Key People | ||
David Wolf Executive Chairman of the Board | Ekaterina Torchilin President, Chief Executive Officer, Director | Francesco Fragasso Chief Financial Officer | Brett Fulton Senior Vice President, General Manager of the HT Inc |
Business Overview |
Hamilton Thorne Ltd. is a provider of precision instruments, consumables, software and services to assisted reproductive technologies (ART), research, and cell biology markets. The Company markets its products and services under the Hamilton Thorne, Gynemed, Planer, Tek-Event, IVFtech, Microptic, and Embryotech Laboratories brands. It also provides an array of third-party equipment and consumables to meet customer requirements. Its branded instrument, equipment and software product lines include precision laser devices, imaging systems, incubators, laminar flow workstations, air purification systems, control rate freezers, lab monitoring systems, and micromanipulation systems. It also offers a portfolio of artificial intelligence (AI)-enabled common astronomy software applications (CASA) software and other product offerings. Its GM501 family of products provides the in vitro fertilization (IVF) lab with comprehensive cell culture media solutions. |
Financial Overview |
For the fiscal year ended 31 December 2023, Hamilton Thorne Ltd revenues increased 16% to $67.2M. Net loss totaled $607K vs. income of $1.9M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net loss reflects General and administrative increase of 38% to $14.9M (expense), Sales and marketing increase of 20% to $14.8M (expense). |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $229.19M as of Dec 31, 2023 |
Annual revenue (TTM): | $92.57M as of Dec 31, 2023 |
EBITDA (TTM): | $9.98M as of Dec 31, 2023 |
Net annual income (TTM): | -$0.84M as of Dec 31, 2023 |
Free cash flow (TTM): | $0.36M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | $25.09M as of Dec 31, 2023 |
Shares outstanding: | 152,124,765 as of Dec 31, 2023 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |